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Abstract
Background: Jaundice and hepatic dysfunction have been reported in patients with thyrotoxicosis and could be due to
different mechanisms.
Objective: To describe three cases of  jaundice occurring in patients with thyrotoxicosis and to illustrate the importance of
early institution of thionamides when indicated.
Methods: We present the clinical and laboratory features of  three patients presenting within a year with thyrotoxicosis and
jaundice and whose clinical conditions improved remarkably following treatment with thionamides.  In addition, current
literature on the subject is reviewed and summarised.
Results: The three patients presented with goitre and jaundice. None of the patients had received blood products, undergone
scarification markings or experienced any previous episode of jaundice. Thyroid function tests in the three patients were
consistent with a diagnosis of thyrotoxicosis. Liver function tests showed elevated bilirubin and transaminases. All patients
improved remarkably following treatment with thionamides.
Conclusion: It is important to rule out thyrotoxicosis in patients with jaundice of unknown cause and consider early use
of thionamides for treatment of the thyrotoxicosis, if confirmed.
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Introduction
Thyrotoxicosis presenting with jaundice and
abnormalities in liver function tests, though not
common, has been reported in literature1-3. Jaundice
in patients with thyrotoxicosis could be due to the
thyrotoxicosis itself, could be as a result of drug
treatment of the thyrotoxicosis, could be due to
conditions associated with autoimmune thyroid
disease like autoimmune hepatitis or could be due
to unrelated conditions like sepsis or viral hepatitis.
We report three patients who presented to our
hospital within the same year with thyrotoxicosis,
jaundice and hepatic dysfunction.
Case 1
A 27 year old female presented with a four day
history of  jaundice, fever, diarrhoea and vomiting.
She did not have a past history of jaundice or history
of indiscriminate use of injections, multiple sexual
partners or blood transfusion.
Physical examination revealed a toxic-looking young
woman, wasted, not pale, deeply icteric, febrile and
dehydrated. She had a staring gaze with bilateral
proptosis. Pulse rate at presentation was 162 beats
per minute, regular and blood pressure was 138/
70mmHg. Abdominal examination revealed tender
hepatomegaly 2cm below the right costal margin
(liver span 13cm).  Other systems were normal.
She had a goitre which was smooth, diffuse, and
non-tender. An assessment of  Graves’ disease with
probable autoimmune hepatitis was made. Thyroid
function tests showed  freeT4 >70 (normal 9-20)
pmol/L, T3 3.5 (normal 1.1-3.2)nmol/L,TSH
0.4(normal 0.38-3.8)mIU/L. Hepatitis B surface
antigen, anti-HCV and retroviral screening were
negative. Serial tests of hepatic function during
admission are as shown in table 1. She was
commenced on antibiotics without significant
improvement.  Later on, propanolol and carbimazole
were commenced and she made significant
improvement with resolution of the jaundice. She
was discharged after two months to be followed
up in the endocrine clinic.
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Table 1: Serial tests of  hepatic function
Week  1 Week 2 Week 3 Week 4 Normal values
AST (IU/L) 70 398 247 224 0-37
ALT (IU/L) 57 425 248 174 0-40
ALP (IU/L) 74 134 99 99 30-150
Total protein (mg/dl) 6.1 9.6 7.5 7.6 6.0-8.0
Albumin (mg/dl) 2.5 4.0 3.1 3.2 3.5-5.0
Bilirubin total (mg/dl) 14.0 17.5 - 13.9 0.2-1.0
Bilirubin conjugated (mg/dl) 11.4 9.2 - 7.9 0-0.4
AST- aspartate aminotransferase, ALT- alanine aminotransferase, ALP- alkaline phosphatase
Case 2
A 39 year old female presented with 8 months history
of an anterior neck swelling, two weeks history of
fever, headache and vomiting and nine days history
of jaundice.  There were associated palpitations, heat
intolerance, warm sweaty palms and progressive
weight loss.
She had not received blood products, undergone
scarification markings or experienced any previous
episode of jaundice. Physical examination revealed
an ill-looking young woman, wasted, pale, deeply
icteric, febrile, with bilateral proptosis and lid
retraction. Pulse rate at presentation was 120 beats
per minute, regular and blood pressure of 160/
60mmHg. She had a goitre measuring 5 by 4cm each
on the left and right lateral lobes. Other systems were
essentially normal.  An assessment of  thyrotoxicosis
likely Graves’ disease complicated with jaundice to
keep in view sepsis, possibly from gastrointestinal
focus was made.
Thyroid function tests showed elevated T3 10.1
(normal 1.0-3.25)nmol/L,T4 251 (normal 65-
175)nmol/L, TSH<0.1(normal 0.5-6.5)mIU/L
consistent with a diagnosis of  thyrotoxicosis. PT/
PTTKwas deranged with an INR of 1.5.
Tests of  hepatic functions are as shown in table 2.
Sepsis screen did not yield any positive findings.
Thyroid scan showed enlargement of both lobes
of the thyroid gland with homogenous echo pattern
and no nodules or calcification. Abdominal
ultrasonography showed normal liver, biliary tree
and gallbladder with no evidence of biliary
obstruction. Direct Coomb’s test was negative.
She was commenced on antibiotics for a week
without resolution of jaundice. Propanolol and
carbimazole were then commenced and she made
significant improvement with resolution of the
jaundice. She was discharged after two months to
be followed up in the endocrine clinic. However
she defaulted from follow up and has not been seen
in the clinic since discharge.
Table 2: Tests of  hepatic function during admission
Tests 1st 2nd Normal
AST(IU/L) 176 237 0-37
ALT (IU/L) 114 30 0-40
ALP (IU/L) 142 54 30-150
Total protein (mg/dl) 7.5 6.1 6.0-8.0
Albumin (mg/dl) 3.3 2.9 3.5-5.0
Bilirubin total (mg/dl) 20.7 5.7 0.2-1.0
Bilirubin conjugated (mg/dl) 15.7 4.1 0-0.4
AST- aspartate aminotransferase, ALT- alanine aminotransferase, ALP- alkaline phosphatase
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Case 3
A 29 year old female presented with 6 months history
of anterior neck swelling, 2 weeks history of jaundice
and a day history of  tremulousness. There was a
history of  bilateral eye protrusion and weight loss.
She had not received blood products, undergone
scarification markings or experienced any previous
episode of jaundice.  Physical examination revealed
a toxic-looking young woman, wasted, pale, deeply
icteric, febrile, and dehydrated. She had a staring gaze
and bilateral proptosis, lid lag and lid retraction.
Abdominal examination revealed diffuse tenderness
with a firm tender hepatomegaly of  4cm below the
right costal margin. Liver span was 16cm. Spleen
was tipped and tender. There was no ascites.
Neurologic examination revealed a conscious and
confused woman with no cranial nerve deficit. Tone
and power was normal but reflexes were hyperactive.
Cardiovascular and respiratory systems were normal.
She had a goitre with right and left lobes measuring
6 by 4cm and 5 by 2 cm respectively, smooth, soft,
and non-tender. An assessment of  thyroid storm
with a background thyrotoxicosis most likely
Graves’ disease complicated by hepatitis was made.
Thyroid function tests showed elevated
freeT3 4.50 (normal 0.92-2.33)pmol/L, free T4
68.73(normal 9-20) pmol/L, TSH<0.05(normal
0.25-5.0) mIU/L. PTTK was deranged with an INR
of  1.3. Tests of  hepatic function showed total
bilirubin 4.0 (normal 0.2-1.0)mg/dl, alanine
aminotransferase 134(0-40) I.U/L, aspartate
aminotransferase 202 (0-37) I.U/L, alkaline
phosphatase 103 (30-150) I.U/L, total protein
7.7mg/dl (6.0-8.0)g/dl, albumin 2.1mg/dl (3.5-
5.0)g/dl. Hepatic function tests could not be
repeated due to financial constraints. She was
commenced on aldactone, intranasal oxygen therapy,
propanolol, carbimazole and anti-liver failure
regimen. She made significant improvement
thereafter with disappearance of the jaundice and
restlessness. She was discharged after 3 weeks to be
followed up in the endocrine clinic. She is currently
doing well and thyroid function has improved
remarkably.
Discussion
A complex relationship exists between the thyroid
gland and the liver. Thyroid hormones are important
for normal hepatic function while the liver is also
important in the metabolism of  thyroid hormone4.
This may explain why abnormalities of  the thyroid
gland can occur in persons with diseases of the liver
while various liver abnormalities can also occur in
persons with diseases of the thyroid.
We have chosen to report these cases for the
following reasons: to show that it is not a very rare
occurrence (the three patients presented within a
year), to highlight the different ways in which they
presented, to raise awareness that hyperthyroidism
can be an incidental finding in a patient presenting
with jaundice so it should be a consideration and to
show that early treatment with thionamides can lead
to resolution of  the jaundice. To the best of  our
knowledge, our report is the first to highlight this
number of cases of thyrotoxicosis and jaundice
presenting within a short period of time in Nigerian
patients.
The three patients described all presented
with fever and jaundice in addition to features of
hyperthyroidism. Like an average clinician, we initially
suspected possible septicaemic illness or viral hepatitis
which led to management along those lines but none
of the patients responded. Improvement was only
noticed in each case after commencing carbimazole.
This implies that the cause of jaundice was probably
the thyrotoxicosis itself.
Liver injury in thyroid disease can be hepatitic or
cholestatic5. The mechanism underlying the hepatic
damage seen in thyrotoxicosis is not clear; however
different functional and histological changes have
been reported. Hepatic injury from thyrotoxicosis
can be induced by ischemic injury. Hyperthyroidism
causes an increase in the metabolic rate which then
induces a relative decrease in blood flow to certain
areas of  the liver resulting in hypoxic injury. Thyroid
hormones might also have a direct toxic effect on
hepatic tissue6.
A common reason for co-existence of
thyrotoxicosis and jaundice is liver injury induced by
several medications, including thionamides which are
used in the treatment of hypertoxicosis7-10. This was
not the case with all our cases as they were not
previously diagnosed with thyrotoxicosis and had
not received antithyroid medications prior to
presentation. Increased levels of transaminases have
been seen following initiation of thionamides and
this usually occurs within the first few months of
treatment10, 11. Occasionally fulminant hepatic failure
occurs. A challenging decision for us was whether
to use anti-thyroid agents for these patients knowing
that the side effects of the drugs rarely include hepatic
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injury. The estimated incidence of  antithyroid
associated hepatotoxicosis with both carbimazole
and propylthiouracil varies but has been put between
0.1-0.2 percent12. Older age and higher dose of these
drugs are risk factors for hepatic injury. Hepatic
function should therefore be monitored routinely
during treatment. Other options that have been
successfully used in cases of antithyroid-induced
hepatotoxicity include substituting antithyroid agents,
use of cholestyramine and radioiodine 9, 11, 13.
Other associations between liver dysfunction
and thyroid disease include autoimmune hepatitis
which is associated with autoimmune thyroid disease
14. The diagnosis of autoimmune hepatitis can only
be made after liver biopsy so a liver biopsy is
indicated if raised liver enzymes persist after
treatment of thyrotoxicosis15 .
A limitation of our reports is inability to do
liver biopsy in any of the patients, partly due to
financial constraints, and partly because our patients
all responded to treatment of  thyrotoxicosis.
Conclusion
Patients with thyrotoxicosis may have abnormal
results of liver function test ranging from mild to
severe. Patients presenting with jaundice of unknown
cause require close examination and investigations
to rule out thyrotoxicosis as the primary cause and
prompt institution of thionamides if and when
indicated.
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